Jounce Therapeutics

Research Associate / Senior Research Associate, Discovery

Job ID
Research & Development
Job Location

Role / Responsibilities

Jounce is looking for a Research Associate/Senior Research Associate Scientist specializing in in vitro biology to join our Discovery Immuno-Oncology Team. The successful candidate will be highly motivated bench scientist committed to elucidating the mechanism of action, and enabling the development, of novel cancer immunotherapeutic biologics. They will generate data to support key decisions for project teams and actively participate in the interpretation of data and design of experiments. They will have the opportunity to work independently and collaboratively to advance portfolio programs in a dynamic and fast-paced environment. 



  • Performance of immune cell-based in vitro assays, including primary immune cell isolation, mammalian cell culture, multi-color flow cytometry, ELISA, multiplex technologies and proliferation assays; 
  • Data analysis and thorough documentation of work in the Company’s eLN system; 
  • Presentation of results in team meetings and other group settings; 
  • Working cross-functionally as part of internal multi-disciplinary project teams; and 
  • Maintaining a safe and clean laboratory environment following all precautions required for a BSL2/BSL2+ setting. 


  • B.S./M.S. in biology, biochemistry, immunology or related discipline with 1+ years relevant experience (industry preferred); 
  • A working knowledge of fundamental immunological principles; 
  • Experience with cell-based functional assays using primary immune cells, such as MLR, and T cell activation/proliferation assays strongly preferred; 
  • Hands-on experience with primary human immune cell culture and differentiation, flow cytometry cell phenotyping and multiplex ELISA systems strongly preferred; 
  • Ability to follow defined procedures and protocols, and strong attention to detail;  
  • Willingness to learn new research methods and a desire for continued learning and development; 
  • Excellent organization and record-keeping skills; 
  • Demonstrated accountability and responsibility for own work; and 
  • Ability to work both independently and in a team setting. 


Jounce Therapeutics is an equal opportunity employer and does not discriminate in its employment decisions on the basis of race, color, national origin, age, physical or mental disability, marital status, religion, creed, sex, or political beliefs. We offer a competitive salary and benefits package. All applicants should be legally entitled to work for any employer in the U.S.

Company Summary

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce’s internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc.


Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
Share on your newsfeed